Predictive Genetic Testing and Consumer Genomics Market Report 2025

The genetic testing and consumer genomics market size has grown rapidly in recent years. It will grow from $7.83 billion in 2024 to $9.07 billion in 2025 at a compound annual growth rate (CAGR) of 15.7%. The growth during the historic period can be attributed to an increasing emphasis on early disease detection and risk assessment, greater affordability and accessibility of genetic testing technologies, rising consumer interest in ancestry and trait analysis, the expansion of telehealth platforms, and the growing prevalence of chronic and hereditary diseases.

The genetic testing and consumer genomics market size is expected to see rapid growth in the next few years. It will grow to $16.14 billion in 2029 at a compound annual growth rate (CAGR) of 15.5%. The growth in the forecast period can be attributed to the rising demand for personalized healthcare and preventive medicine, increasing availability of direct-to-consumer genetic testing kits, growing integration of genomics into clinical decision-making, expanding investments in biotechnology and genetic research, and strengthened government support for genomic research and precision medicine initiatives. Key trends anticipated during this period include advancements in next-generation sequencing (NGS), the integration of artificial intelligence (AI) and machine learning in genetic data analysis, progress in portable and at-home testing technologies, the incorporation of genetic data into electronic health records (EHRs), and continued developments in microarray technology.

The growing awareness of personalized medicine is expected to drive the growth of the predictive genetic testing and consumer genomics market. Personalized medicine is a medical approach that tailors treatment and preventive strategies to an individual’s genetic makeup, lifestyle, and environmental factors. Awareness is increasing due to its potential to enhance treatment effectiveness by aligning therapies with a patient’s unique biological characteristics. Predictive genetic testing and consumer genomics support personalized medicine by identifying genetic risks and traits, which enable early diagnosis, tailored prevention, and customized treatment plans. For example, in February 2024, the Personalized Medicine Coalition, a US-based professional membership organization, reported that the Food and Drug Administration (FDA) approved 16 new personalized medicines in 2023, up from 6 in 2022. Therefore, the rising awareness of personalized medicine is fueling the expansion of the predictive genetic testing and consumer genomics market.

Leading companies in the predictive genetic testing and consumer genomics market are developing innovative solutions, such as consumer genomics insight services, to provide individuals with personalized health information and support early detection of genetic risks. Consumer genomics insight services involve direct-to-consumer genetic testing that analyzes DNA to deliver personalized information on ancestry, health risks, traits, and overall wellness, without requiring a medical prescription. For instance, in November 2022, Strand Life Sciences Private Limited, an India-based technology firm, launched Strand Genomic Wellness to provide personalized health insights. This solution helps individuals understand their genetic predispositions to various conditions, promoting proactive health management and preventive care based on genomic data. It enables individuals and healthcare providers to make informed medical and lifestyle decisions using personalized genetic information.

In April 2025, Illumina Inc., a US-based biotechnology firm, partnered with Tempus AI Inc. to promote the clinical adoption of precision medicine. The collaboration aims to integrate advanced genomic artificial intelligence (AI) and multimodal data to make comprehensive molecular profiling a standard component of patient care across multiple disease areas. Tempus AI Inc., a US-based health technology company, leverages AI-powered genomic analysis to enhance predictive genetic testing and consumer genomics solutions.

Major players in the predictive genetic testing and consumer genomics market are Thermo Fisher Scientific Inc., Abbott Laboratories, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, QIAGEN N.V., Ancestry.com, Myriad Genetics Inc., ARUP Laboratories, BGI Genomics Co. Ltd., Invitae Corporation, Guardant Health Inc., 23andMe Inc., Helix Inc., Color Health Inc., Mapmygenome India Ltd., Reliance Life Sciences, Dante Labs Inc., EasyDNA, Gene by Gene Ltd., Nebula Genomics Inc., and Pathway Genomics Corporation.

North America was the largest region in the predictive genetic testing and consumer genomics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in predictive genetic testing and consumer genomics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the predictive genetic testing and consumer genomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The predictive genetic testing and consumer genomics market includes revenues earned by entities by providing services such as disease risk assessment, carrier screening, and ancestry and ethnicity testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The predictive genetic testing and consumer genomics market research report is one of a series of new reports that provides predictive genetic testing and consumer genomics market statistics, including the predictive genetic testing and consumer genomics industry's global market size, regional shares, competitors with the predictive genetic testing and consumer genomics market share, detailed predictive genetic testing and consumer genomics market segments, market trends and opportunities, and any further data you may need to thrive in the predictive genetic testing and consumer genomics market. This predictive genetic testing and consumer genomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Predictive genetic testing and consumer genomics involve the analysis of an individual’s DNA to evaluate their risk of developing specific genetic conditions or traits, while also offering personalized insights into health, ancestry, and lifestyle. These services are available either directly to consumers or through healthcare professionals, using genetic data to support preventive health decisions or satisfy personal curiosity about genetic heritage.

The primary testing types within predictive genetic testing and consumer genomics include diagnostic testing, predictive testing, pharmacogenomic testing, and carrier screening. Diagnostic testing is used to confirm or exclude genetic disorders in individuals already exhibiting symptoms. Technologies utilized in these services include polymerase chain reaction (PCR), next-generation sequencing (NGS), microarray technology, and DNA sequencing. Service offerings range from genetic counseling and sample collection to data analysis, interpretation, and reporting. Applications cover a wide spectrum, including breast and ovarian cancer, cardiovascular screening, diabetes monitoring, colon cancer, Parkinson’s and Alzheimer’s disease, urologic and prostate cancer screening, orthopedic and musculoskeletal conditions, and various other cancer and disease screenings. The main end users of these services include healthcare providers, research institutions, diagnostic laboratories, and consumers through direct-to-consumer testing platforms.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.